CHiR-DEL
Phase 2Small molecule
CHiR-DEL is one of 14 small molecule programs targeting Elderly. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Elderly
#DrugCompanyPhaseTrials
1Venclexta
AbbVieApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
AZD0486
AstraZenecaPhase 3
Decadron
AAspen Global Incorporated
Phase 2
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
R Mini CHOP
AstraZenecaPhase 3
R-Gemox
HHutchmed
Phase 2
Azacytidine
AArog Pharmaceuticals, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CHiR-DEL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details